Welcome to the fifth issue of the Refractory Asthma Stratification Programme (RASP-UK) newsletter, you can download it here [1].
RASP-UK underwent its third progress review by the MRC on 19 May. Recruitment was high up on the list of topics discussed but the Group were reassured by the plans which each of the work-strand teams have put in place around recruitment. The Group was pleased to see the addition of new partners like Boehringer Ingelheim and impressed by the patient involvement within the consortium. There were also discussions on data collection and curation and how the team plan to adopt learnings from previous MRC programmes. In conclusion, the Group agreed that the consortium was progressing well and that we are on target to deliver the programme.
Since the last newsletter we have extended the survey to reach consensus on aspects of biomarker based corticosteroid adjustment in severe asthma to UK severe asthma physicians out with RASP-UK, as well as members and collaborators with the European Severe Asthma Clinical Research Collaboration Severe Heterogenous Asthma Research collaboration, Patient-centered (SHARP) and patients with severe asthma from Asthma UK’s network. The survey is currently being extended to Australian respiratory physicians. A summary of the results to date are provided.
In Workstrand 1 we are now just over two thirds of the way towards our target of 300 patients randomised. To date, we have 216 confirmed patients randomised from 395 patients screened. Our dropout rate continues to be low, at around 10%, and we now have over 60 patients who have completed the study. Our target is 300 patients randomised by the end of December 2017. For Workstrand 2 all of the eight sites are now open to recruitment. Twenty patients have completed and there are serveral with appointments booked. Guy’s and St Thomas’s Hospital has now joined us as the final site to open in the SoMOSA trial, and after a bumpy start are up and screening for Workstrand 3. Our first Work-strand 4 study has just received ethical approval. The mepolizumab exacerbation study is an investigator led study sponsored by QUB and funded using the additional contribution received by RASP-UK when the new industrial partners joined the programme.
The newsletter reminds everyone that the RASP-UK website holds copies of all relevant study documents that can be accessed via the consortium website [2].
References
Welcome to the seventh issue of the Refractory Asthma Stratification Programme (RASP-UK) newsletter
ive years ago I was lucky enough to be involved in a project that resulted in publications
Every year, a huge amount of scientific data is released. It's out there, but how do you find it?
It was encouraging to see so many partners at the 2017 General Assembly meeting last December
Investigator-Initiated Clinical Trials (IITs) are clinical studies led by academic researchers or clinicians
The UK's world-class human challenge study gives us new information about SARS-CoV-2 cases that were mild in 36 healthy.
Investigator sites are very important to clinical studies because they make sure that new drugs are safe and work well.
Get our latest news and publications
Sign up to our news letterResources
Social
Contact us
Address
Niche Science & Technology
Unit 26 Falstaff House
Bardolph Road
Richmond TW9 2LH
United Kingdom
